Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Oncology Office Director Will Be Selected In Next Few Weeks

This article was originally published in The Pink Sheet Daily

Executive Summary

The selection of a director for the new Office of Oncology Drug Products will be finalized in the next few weeks, FDA said

You may also be interested in...

CDER Move To White Oak Site Delayed Until July

The move, which had been scheduled for April, has been pushed back because the building is not ready, FDA says. The CDER reorganization is also being delayed to coincide with the move.

FDA Will Conduct "National Search" For Head Of Oncology Office

The agency formally announces creation of an Office of Oncology Drug Products. The new director will oversee the consolidation of three areas within the Center for Drug Evaluation & Research currently responsible for cancer drug reviews.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts